Feb 24, 2026 8:45am EST MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
Jan 20, 2026 10:15am EST MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
